EIQ.XA is trading 29.3% up at A$1.60 driven by a strategic investment and commercial partnership with Pro Medicus, alongside new U.S. leadership appointments. - Pro Medicus (ASX: PME) has agreed to an initial A$10 million investment via secured convertible notes, with an option for an additional A$10 million upon FDA clearance of EchoSolv HF. - Pro Medicus will also become the proposed U.S. reseller of Echo IQ's EchoSolv product suite, providing access to an extensive network of leading U.S. health systems. - Echo IQ has also appointed Matthew Dodds as CFO and Dr. Vinod Thourani as Clinical Advisor to strengthen its executive team, U.S. presence, and accelerate FDA regulatory progress.